Compare DRD & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRD | ZLAB |
|---|---|---|
| Founded | 1895 | 2013 |
| Country | South Africa | China |
| Employees | 3410 | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.0B |
| IPO Year | N/A | 2017 |
| Metric | DRD | ZLAB |
|---|---|---|
| Price | $21.10 | $20.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $32.63 | ★ $49.60 |
| AVG Volume (30 Days) | 367.0K | ★ 874.3K |
| Earning Date | 08-19-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.24% | N/A |
| EPS Growth | N/A | ★ 38.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $460,156,000.00 |
| Revenue This Year | $39.23 | $9.75 |
| Revenue Next Year | $30.12 | $26.03 |
| P/E Ratio | $15.32 | ★ N/A |
| Revenue Growth | N/A | ★ 15.33 |
| 52 Week Low | $13.25 | $15.96 |
| 52 Week High | $39.37 | $41.20 |
| Indicator | DRD | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 39.48 | 68.60 |
| Support Level | $20.13 | $16.84 |
| Resistance Level | $32.74 | $21.33 |
| Average True Range (ATR) | 0.82 | 0.75 |
| MACD | 0.10 | 0.29 |
| Stochastic Oscillator | 40.58 | 93.73 |
DRDGold Ltd is a South African gold mining company engaged in surface gold tailings retreatment including exploration, extraction, processing, and smelting. Its reportable operating segments are; Ergo, FWGR, and Corporate office and other reconciling items. The Ergo is a surface gold retreatment operation that treats old slime dams and sand dumps to the south of Johannesburg's central business district as well as the East and Central Rand goldfields, and the FWGR which is a surface gold retreatment operation and treats old slime dams in the West Rand goldfields. The Ergo segment derives a vast majority of the company's revenue.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.